EuroAPI halts production at Italian plant

Because of quality control issues, the Sanofi spinoff EuroAPI will halt output of all active pharmaceutical ingredients (APIs) at its plant in Brindisi, Italy. The site produces 11 APIs and intermediates, most of which are anti-infectives such as spiramycin, rifaximin, rifampicin, and teicoplanin. Amid growing competition, EuroAPI announced earlier this year that it will stop making 13 money-losing APIs and close some European sites.